CommercialPrior AuthMedium impact
Elotuzumab (Empliciti®
BCBS Tennessee·TN · Oncology, Hematology·Medical Policy
Effective date
Jul 31, 2026
We identified it
Jun 17, 2026
Summary
BlueCross BlueShield of Tennessee has established a new medical policy for Elotuzumab (Empliciti®) that will require prior authorization for multiple myeloma and related conditions. The policy covers FDA-approved indications and specific compendial uses, with 12-month authorization periods when used in approved combination therapies.
Action Required
Before July 31, 2026: Billing team must implement prior authorization requirements for Elotuzumab (Empliciti®) claims. Update billing system to flag cases requiring documentation of combination therapy with lenalidomide/dexamethasone, bortezomib/dexamethasone, or pomalidomide/dexamethasone. Train staff on coverage criteria for multiple myeloma, POEMS syndrome, MIDD, and MGRS conditions. Set up 12-month reauthorization reminders for approved cases.